Pediatric Health

cystic fibrosis lungs
Pediatric Health Pharmacological

FDA Grants SPIRO-2101 CF Treatment Orphan Drug and Rare Pediatric Disease Designations 

Spirovant Sciences, a gene therapy company developing treatments and cures for genetic lung diseases including cystic fibrosis, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug and Rare Pediatric Disease Designations to its lead product candidate, SPIRO-2101, for the treatment of cystic fibrosis. SPIRO-2101, an inhaled […]

oxygen delivery
Pediatric Health Respiratory

New Clinical Guideline on Home Oxygen for Children

The American Thoracic Society has developed a new clinical practice guideline for home oxygen therapy for children. The guideline appears in the Feb. 1 edition of the Society’s American Journal of Respiratory and Critical Care Medicine. “Home Oxygen Therapy for Children: An Official American Thoracic Society Clinical Practice Guideline”   makes specific recommendations […]

orkambi for cystic fibrosis
Pediatric Health Pharmacological Sleep Disorders

FDA Approves ORKAMBI®, First Medicine to Treat the Underlying Cause of CF for Children Ages 2-5 Years with Most Common Form of the Disease

Vertex Pharmaceuticals Incorporated announced the U.S. Food and Drug Administration (FDA) has approved ORKAMBI® (lumacaftor/ivacaftor) to include use in children ages 2 through 5 years with cystic fibrosis (CF) who have two copies of the F508del-CFTR mutation, making it the first medicine approved to treat the underlying cause of CF […]